No connection

Search Results

INBS vs ISPC

INBS
Intelligent Bio Solutions Inc.
BEARISH
Price
$2.46
Market Cap
$4.9M
Sector
Healthcare
AI Confidence
95%
ISPC
iSpecimen Inc.
BEARISH
Price
$0.13
Market Cap
$3.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
INBS
--
ISPC
--
Forward P/E
INBS
7.03
ISPC
-0.16
P/B Ratio
INBS
0.27
ISPC
0.41
P/S Ratio
INBS
1.37
ISPC
1.97
EV/EBITDA
INBS
-0.5
ISPC
0.32

Profitability

Gross Margin
INBS
46.21%
ISPC
1.25%
Operating Margin
INBS
-290.89%
ISPC
-5192.87%
Profit Margin
INBS
0.0%
ISPC
0.0%
ROE
INBS
-150.2%
ISPC
-327.77%
ROA
INBS
-51.17%
ISPC
-59.44%

Growth

Revenue Growth
INBS
47.6%
ISPC
-96.5%
Earnings Growth
INBS
--
ISPC
--

Financial Health

Debt/Equity
INBS
0.18
ISPC
0.09
Current Ratio
INBS
2.38
ISPC
1.12
Quick Ratio
INBS
2.17
ISPC
1.11

Dividends

Dividend Yield
INBS
--
ISPC
--
Payout Ratio
INBS
0.0%
ISPC
0.0%

AI Verdict

INBS BEARISH

The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.

Strengths
Strong YoY revenue growth of 47.60%
Low Debt-to-Equity ratio (0.18)
Healthy liquidity with a Current Ratio of 2.38
Risks
Critical financial health (Piotroski F-Score 1/9)
Extreme operating losses (Operating Margin -290.89%)
Severe price depreciation (down 79.8% over 1 year)
ISPC BEARISH

The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.

Strengths
Low Debt/Equity ratio (0.09) suggests minimal long-term debt burden
Current Ratio of 1.12 indicates marginal short-term liquidity
Trading at a discount to book value (P/B 0.41)
Risks
Catastrophic revenue decline of -96.50% YoY
Extreme operational inefficiency with -5192.87% operating margin
Severe financial instability indicated by Piotroski F-Score of 1/9

Compare Another Pair

INBS vs ISPC: Head-to-Head Comparison

This page compares Intelligent Bio Solutions Inc. (INBS) and iSpecimen Inc. (ISPC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile